AMC
ABCL icon

Asset Management Corp’s AbCellera Biologics ABCL Stock Holding History

Asset Management Corp’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$271K Sell
36,000
-7,500
-17% -$68.1K 0.21% 100
2022
Q4 		$441K Buy
43,500
+17,000
+64% +$196K 0.37% 73
2022
Q3 		$262K Buy
+26,500
New +$291K 0.16% 125

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Asset Management Corp's ABCL Position: Q1 2023 in Review

Asset Management Corp reduced its AbCellera Biologics (ABCL) stake by 17% in Q1 2023, selling an estimated $68.1K and leaving 36,000 shares worth $271K. The position accounts for 0.21% of the portfolio, ranked #100.

Asset Management Corp first reported a position in ABCL in Q3 2022 and has held it in 3 quarters since. The position peaked at $441K in Q4 2022. 183 funds tracked by Wall St. Rank hold ABCL as of Q1 2023.

  • Asset Management Corp held 36,000 shares of AbCellera Biologics worth $271K as of Q1 2023.
  • Asset Management Corp sold 7,500 AbCellera Biologics shares in Q1 2023, an estimated $68.1K.
  • AbCellera Biologics made up 0.21% of Asset Management Corp's portfolio in Q1 2023, its #100 holding.
  • Asset Management Corp first reported a position in AbCellera Biologics in Q3 2022 and has held it in 3 quarters since.
  • Asset Management Corp's AbCellera Biologics position peaked at $441K in Q4 2022.
  • 183 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2023.

Based on Asset Management Corp's 13F filing for Q1 2023, filed 14 Apr 2023.